ThromboGenics announced that it will regain full global rights to Jetrea (ocriplasmin) from Alcon based on a mutual agreement. Under the terms of the agreement, ThromboGenics will receive a cash amount of €53.7 million ($64.2 million) and a forthcoming equity investment of €10 million ($11.95 million) in ThromboGenics capital.
Jetrea is the first and only approved pharmacological treatment for symptomatic vitreomacular adhesion (VMA) in the US and vitreomacular traction (VMT) in Europe and elsewhere in the world. First introduced in 2013, Jetrea has been approved in 54 countries worldwide, with nearly 30,000 patients being treated in about 20 countries.
“We are pleased to have reached this agreement with Alcon and Novartis in relation to the non-US rights to Jetrea. We intend to take time to evaluate how best to capitalize on the global opportunity that we now have with Jetrea," Patrik De Haes, MD, CEO of ThromboGenics, said in a company news release. "In the near term, it is our key priority to secure the continuity of care by ensuring that patients and physicians have timely access to this unique pharmacological treatment for symptomatic vitreomacular adhesion/ traction (sVMA/VMT). We look forward to working with Novartis during this important transition period.”
Dr. De Haes continued, “We are also pleased to welcome Novartis as a shareholder in ThromboGenics as we are developing our pipeline of novel treatments for diabetic eye disease. The significant funds that we have received today will allow ThromboGenics to develop its pipeline of novel disease-modifying drug candidates which are targeting all of the key segments of the diabetic eye disease market.”